Fidelity Health Care vs. State Street Biotech: Which ETF Fits Your Portfolio Best?
One offers broad stability with lower costs and higher income, while the other chases biotech growth with 89.3% annual returns but steeper volatility.
Overview
The Fidelity MSCI Health Care Index ETF (NYSEMKT:FHLC) may appeal to cost-conscious investors seeking broad stability, whereas the State Street SPDR S&P Biotech ETF (NYSEMKT:XBI) targets growth through a narrow, higher-cost focus.
Healthcare is a pillar of the market, but investors must choose between broad stability and niche volatility. One fund targets high-reward biotech, while the other provides a diversified anchor across pharmaceuticals and services. This comparison evaluates how these different scopes affect cost and returns.
Beta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.
Details
Source
Originally published at www.fool.com.